Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Dow
Moodys
Harvard Business School
Express Scripts
Baxter
Mallinckrodt

Last Updated: December 14, 2019

DrugPatentWatch Database Preview

Litigation Details for HORIZON PHARMA AG v. WATSON LABORATORIES, INC. - FLORIDA (D.N.J. 2013)

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

HORIZON PHARMA AG v. WATSON LABORATORIES, INC. - FLORIDA (D.N.J. 2013)

Docket   Start Trial Date Filed 2013-08-26
Court District Court, D. New Jersey Date Terminated 2016-03-01
Cause 35:271 Patent Infringement Assigned To Noel Lawrence Hillman
Jury Demand None Referred To Magistrate Judge Joel Schneide
Parties ACTAVIS LABORATORIES FL, INC.; ACTAVIS PHARMA, INC.; ACTAVIS, INC.; ANDRX CORPORATION; HORIZON PHARMA AG; JAGOTEC AG; WATSON LABORATORIES, INC. - FLORIDA
Patents 6,488,960; 6,677,326; 8,168,218; 8,309,124; 8,394,407
Attorneys ARNOLD B. CALMANN; CHRISTOPHER J. BORCHERT; ELEONORE OFOSU-ANTWI; GERI L. ALBIN; JEFFREY S. SOOS; JENNIFER C. CRITCHLEY; JOHN F. BRENNER; KAREN A. CONFOY; LIZA M. WALSH; MELISSA ANNE CHUDEREWICZ; TRICIA B. O'REILLY
Link to Docket External link to docket
Small Molecule Drugs cited in HORIZON PHARMA AG v. WATSON LABORATORIES, INC. - FLORIDA
The small molecule drug covered by the patents cited in this case is   Start Trial .

Details for HORIZON PHARMA AG v. WATSON LABORATORIES, INC. - FLORIDA (D.N.J. 2013)

Date Filed Document No. Description Snippet Link To Document
2014-11-10 104 those patents: U.S. Patent No. 8,394,407 (the “’407 patent”) and U.S. Patent No. 8,309,124 (the … (Abstract, ’124 Patent at 2 and Abstract, ’407 patent at 2) The patents suggest that the invention…filed the ’124 patent on March 19, 2012 (issued November 13, 2012) and the ’407 patent on March 23, 2012… assignment, both patents now belong to Plaintiff Jagotec. Both patents concern the “Delayed…stiffness and pain. (’124 Patent at 5, col. 1, ll. 40-56 and ’407 patent at 6, col. 1, ll. 31-47) External link to document
2013-11-12 21 expiration of U.S. Patent Nos. 6,488,960 (“the ’960 patent”), 6,677,326 (“the ’326 patent”), 8,309,124 (“…owner of U.S. Patent Nos. 6,488,960 (“the ’960 patent”) and 6,677,326 (“the ’326 patent”). 8…(“the ’124 patent”), 8,168,218 (“the ’218 patent”) and 8,394,407 (“the ’407 patent”). Watson denies the… owner of U.S. Patent Nos. 8,308,124 (“the ’124 patent”), 8,168,218 (“the ’218 patent”) and 8,394,407…AS TO THE ALLEGED PATENTS-IN-SUIT 23. Watson admits that the ’960 patent is titled “Corticosteroid External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
McKesson
Baxter
AstraZeneca
Mallinckrodt
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.